Capsigen, Inc.
https://capsigen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Capsigen, Inc.
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss
BIIB112, the gene therapy candidate Biogen picked up in $877m acquisition of Nightstar, missed its primary endpoint in X-linked retinitis pigmentosa. Phase III data for BIIB111, also from Nightstar, are expected soon.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy